Offering products that women want

Daré is committed to identifying, licensing and developing candidates that expand options, improve outcomes, and enhance safety for women across the broad spectrum of reproductive health. 

Non-hormonal monthly contraceptive - Ovaprene™

Ovaprene™ is a clinical stage, non-hormonal contraceptive ring intended to provide protection over multiple weeks of use, require no intervention at the time of intercourse, and fill a void in today’s contraception method mix. It represents a new approach to contraception and if approved, will represent a new birth control category. 

Different by design

Today, there is a need for a safe non-hormonal contraceptive method that does not require action at the time of intercourse and that provides a level of “typical use”   contraception effectiveness approaching that of hormones. The most popular short-acting non-hormonal contraceptive options include condoms and spermicides, methods that lack convenience and have modest “typical use”  efficacy ranging from 72-82%.​

We believe that a non-hormonal monthly contraceptive ring that is convenient (inserted and worn for multiple weeks), safe and demonstrates typical use effectiveness comparable to diaphragms, pills, patches and hormonal rings (which have 88-91% contraceptive effectiveness in “typical use”) has the potential to capture market share across the broad spectrum of short-acting methods, primarily from non-hormonal contraceptive users and current non-users of any form of contraception, but also from a small segment of hormonal contraceptive users.​

Women value convenience and safety. Most women would prefer a contraceptive method they don’t need to remember to take every day and that does not require action at the time of intercourse. A contraceptive ring, whose monthly use is initiated and controlled by a woman, has numerous attributes that women find appealing:

  • An estimated 67% of women said that a monthly vaginal ring has most of the features they deemed extremely important.
  • Nearly 85% would prefer a monthly option with a lower hormone dose than the oral birth control pill.
  • An estimated 80% of women currently use a non-coital dependent method.

Ovaprene™ is designed to provide multiple weeks of contraceptive protection without the use of hormones. ​

Ovaprene™ has a custom intravaginal ring design, with a permeable mesh in the center a small silicone ring that creates a partial barrier to sperm, and a mechanism to release locally acting spermiostatic agents through the ring. The silicone ring releases ingredients – ascorbic acid and ferrous gluconate – which act together to create a spermiostatic environment. The non-braided multi-filament mesh component functions as a physical barrier to sperm. The unique combination of these two complementary approaches seeks to produce attractive contraceptive efficacy outcomes that are consistent with the most effective barrier option, the diaphragm, and short-acting hormonal options (pill, patches and vaginal ring) that provide 88-91% effectiveness in “typical use”.

Encouraging Results To Date

In a pilot clinical study conducted in 21 women, Ovaprene™ demonstrated the ability to immobilize sperm and prevent their progression into the cervical mucus. The study also demonstrated the acceptability of the device to both partners. No serious adverse events were reported. (Journal of Reproductive Medicine 2009; 54:685–690)

​Ongoing Clinical Development

The FDA previously determined that the division to lead the review of Ovaprene™ will be the Center for Devices and Radiological Health (CDRH ) and that Premarket Approval, or PMA, from the FDA will be necessary to market Ovaprene™ in the United States. We believe the clinical development plan for Ovaprene™ will be guided by the size, structure and results of other barrier contraceptive devices using active agents that obtained approval from CDRH. We believe those other product development plans leading to FDA approvals provide a good indication of the FDA requirements likely to be required for Ovaprene™. Specifically, in addition to demonstrating biocompatibility and safety, we expect the clinical requirements for FDA approval for Ovaprene™ to be:  • obtaining safety and preliminary efficacy data in a postcoital test (“PCT”  ) clinical trial, and • conducting one large, single arm safety and efficacy study, the pivotal clinical trial. 

PCT Clinical Trial

We intend to conduct the PCT clinical trial for Ovaprene™ in collaboration with a leading organization in contraceptive research, CONRAD, which was established in 1986 under a cooperative agreement between Eastern Virginia Medical School and the U.S. Agency for International Development (USAID). CONRAD has conducted PCT studies on numerous currently FDA approved barrier methods of contraception, and conducted the PCT and pivotal trials for the Caya® diaphragm, the most recent barrier contraceptive to receive approval through CDRH. Contraceptive PCTs are generally conducted in 15-30 subjects.

Pivotal Clinical Trial

Assuming positive results from our planned PCT clinical trial of Ovaprene™, our intention is to conduct a pivotal contraceptive efficacy clinical trial of similar size and duration as Caya®. Caya®’s contraceptive pivotal study evaluated pregnancy rates in approximately 250 women over a period of six months. Prior to the completion of the U.S. pivotal study of Ovaprene™, we may seek a CE Mark approval for Europe using a subset of the total pivotal clinical trial population. The receipt of E.U. or U.S. regulatory approvals can be used to support registration in many other countries around the world.

​Looking Toward The Future 

At Daré, we are committed to developing a portfolio that expands options, improves outcomes, and enhances safety across a spectrum of reproductive health needs for women worldwide. With this goal in mind, in addition to Ovaprene™, we have identified other potential product candidates in women’s reproductive health that meet these selection criteria. We are in discussions with the owners of these products as we may seek to license such products to build a product pipeline over time.

Female Sexual Arousal Disorder (FSAD) – Topical Sildenafil

Topical Sildenafil for Women with FSAD

Female sexual arousal disorder (FSAD) is characterized by a persistent or recurrent inability to attain or to maintain sexual arousal until the completion of sexual activities.1  As many as thirty-three percent of women in the U.S. (21 to 60 years old) experience symptoms of low or no sexual arousal.2  Up to an estimated ten million women in the U.S. are affected and/or distressed by this condition and seek a solution to improve their condition.3

There are no approved products in the U.S. that specifically address the symptoms or underlying pathology of FSAD. Orally administered sildenafil received FDA approval in 1998 for the treatment of erectile dysfunction in men and is marketed under the brand name Viagra®.  Oral sildenafil also demonstrated biological activity when studied in women,4 but due to differences between male and female physiology, it is expected that a topically administered formulation of sildenafil (applied directly to the vaginal cavity) may have advantages over the oral formulation.  SST’s Topical Sildenafil formulation is a unique, proprietary topical formulation of sildenafil that is specially formulated for women in a topical cream dosage form and is designed to be applied directly to the genital tissue. Based on known biological pathways for the molecule, Topical Sildenafil is expected to increase local blood flow to the genital tissue, which we believe will lead to an improvement in genital response and overall sexual experience.

More specifically, studies of women have demonstrated that an improvement in genital blood flow is linked to increased arousal and improved sexual experience.5  Sildenafil is known to inhibit PDE5, leading to an increase in smooth muscle relaxation and improved blood flow.6  Our investigational SST Topical Sildenafil formulation is expected to exhibit similar PDE5 inhibitor effects on female genital tissue.  In a Phase 2a trial in women with FSAD, SST’s Topical Sildenafil formulation demonstrated increases in measurable blood flow to the genital tissue when compared to placebo.7

We plan to request a meeting with the FDA to discuss the Phase 2 and 3 trial designs for Topical Sildenafil in FSAD patients in the first half of 2018.  Currently, the planned Phase 2 trial is expected to evaluate the product candidate under real-life conditions in women with FSAD. Clinical endpoints are expected to include patient reported outcomes (PROs) using validated questionnaires, and FDA’s input will be requested on the proposed PROs and questionnaire tools as well.  The objective of the Phase 2 and 3 trials is to establish the efficacy and safety of SST’s Topical Sildenafil for this proposed use in order to support future regulatory applications to bring an important new treatment for women to commercial markets.

1Human Sexuality and Its Problems (Third Edition), 2009
Ad Hoc Market Research: FSAD Prevalence Report (Oct 2015) conducted for SST LLC. 

16% of women are distressed per Ad Hoc Market Research: FSAD Prevalence Report (Oct 2015) conducted for SST LLC.   Based on US Census projections for 2016 this equates to 10 million women.

The Enhancement of Vaginal Vasocongestion by Sildenafil in Healthy Premonopausal Women.   Journal of Women’s Health & Gender-Based Medicine.  Vol. 11, No. 4.  2002; The Effect of Sildenafil Citrate on Uterine and Clitoral Arterial Blood Flow in Postmenopausal Women https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1480594/ 

Safety and Efficacy of Sildenafil Citrate for the Treatment of FSAD: A Double-Blind, Placebo Controlled Study.  The Journal of Urology.  Vol 170, 2333-2338, December 2003.

Viagra® prescribing information, Mechanism of Action Section 12.1, https://www.viagra.com, https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/20895s039s042lbl.pdf

Date on file.